Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Participants must have given documented informed consent, or have a legally authorised representative who has done so.
• Stored tumour tissue from a previous biopsy must be available for use, though exceptions may be considered with approval from the lead study doctor (confirm with trial site).
• Participants must be 18 years of age or older.
• Participants must have a reasonable level of physical functioning, as measured by standard performance scales (KPS ≥ 70% and ECOG ≤ 2 — confirm with trial site if these terms are unfamiliar).
• Participants must have a life expectancy of at least 4 weeks.
• Participants must have a previously confirmed diagnosis of a specific type of brain tumour: glioblastoma (IDH-wildtype), grade 4 IDH-mutant astrocytoma, or a lower-grade astrocytoma (grade 2 or 3) that has now shown signs of progressing to a grade 4 tumour on imaging.
• The tumour must have returned or progressed after standard treatment (such as chemotherapy with or without a tumour-treating device), and at least 12 weeks must have passed since completing front-line radiation therapy.
• Tumour tissue must show specific biological markers when tested by the trial's pathology team: a protein called IL13Rα2 must be present above a certain level, and a gene called EGFR must show specific changes (confirm with trial site).
• Participants must have no known medical reasons preventing them from undergoing a blood cell collection procedure, receiving steroids, having imaging scans, or receiving a drug called tocilizumab.
• Participants must have blood cell counts and organ function within acceptable ranges, including white blood cells, platelets, haemoglobin, liver function, kidney function, and oxygen levels (specific values will be checked by the trial team).
• Participants must test negative for HIV, hepatitis C, and active hepatitis B.
• Female participants who could become pregnant must have a negative pregnancy test before joining.
• Female and male participants who could become pregnant or father a child must agree to use effective contraception or abstain from relevant sexual activity throughout the study and for at least 3 months after the last treatment dose.

Who may not be able to join:

• Participants who are currently receiving a drug called bevacizumab (due to a higher risk of wound-related complications).
• Participants who have not yet recovered from side effects caused by previous treatments.
• Participants who have received a live vaccine within the 30 days before joining the trial.
• Participants with seizures that are not under control, or who have signs of progressive brain dysfunction.
• Participants with a history of significant allergic reactions to substances similar to the study treatment.
• Participants with a serious uncontrolled medical condition.
• Participants with an active autoimmune disease that requires ongoing treatment with immune-suppressing medication.
• Participants with an active infection currently requiring intravenous (IV) antibiotics (minor infections such as a small scalp infection are not automatically disqualifying — confirm with trial site).
• Participants with a known history of HIV, hepatitis B, or hepatitis C infection.
• Participants who currently have another active cancer.
• Females who are pregnant or breastfeeding.
• Participants with any other condition that the lead study doctor believes would make participation unsafe.
• Participants who, in the study doctor's judgement, may not be able to follow all study procedures or requirements.

Important: Always verify eligibility with the trial site directly before applying.